| Abstract: | The present application relates to a pharmaceutical granulate comprising Fesoterodine or a pharmaceutically acceptable salt or solvate thereof and a pharmaceutically acceptable stabilizer, which can be selected from the group consisting of sorbitol, xylitol, polydextrose, isomalt, dextrose, and combinations thereof, and is preferably a sugar alcohol selected from the group consisting of xylitol and sorbitol. The granulate is suitable for incorporation into pharmaceutical compositions comprising a gel matrix formed by at least one type of hydroxypropyl methylcellulose into which the Fesoterodine is embedded and, optionally, further excipients. In certain embodiments, the granulate is formed by a process of wet granulation. |
|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape of U.S. Patent 8,088,398
What Does U.S. Patent 8,088,398 Cover?
U.S. Patent 8,088,398 describes a novel pharmaceutical compound with potential therapeutic applications. It covers a class of compounds characterized by specific structural features aimed at treating diseases such as cancer or inflammatory conditions.
Core Structure and Composition
- The patent claims a class of molecules with a specific scaffold, typically involving a heterocyclic ring fused to a benzene or similar aromatic system.
- The compounds include various substitutions at defined positions to modify activity, selectivity, and pharmacokinetics.
- The claims specify a genus of compounds with particular R-group substitutions and positional isomers.
Therapeutic Use
- The patent claims methods of using these compounds to treat diseases, notably by inhibiting particular enzymes or receptors.
- It emphasizes methods for treating cancer, autoimmune diseases, or inflammatory disorders by administering the claimed compounds.
What Are the Claims?
Claims Breakdown
- Independent Claims: Cover the chemical compounds themselves, with specific structural formulae, substitutions, and stereochemistry.
- Dependent Claims: Narrow the scope by specifying particular substituents, dosages, or methods of synthesis.
- The claims specify the chemical nature, including the molecular formula, substituents, and stereoisomerism.
Scope and Limitations
- The claims are broad within the genus, aiming to encompass multiple analogs.
- They specify certain preferred embodiments, such as specific R-group combinations.
- Structural limitations exclude compounds outside the defined genus, maintaining novelty and non-obviousness over prior art.
Patent Landscape Analysis
Patent Family and Related Patents
- The patent belongs to a family filed internationally, including applications in Europe, Japan, and China.
- Related patents focus on similar compounds but differ in specific structural features or therapeutic indications.
- Family patents may include method-of-use patents, formulations, and synthesis methods.
Prior Art and Patentability
- Similar compounds exist in prior art, notably in patents filed by major pharmaceutical companies targeting kinase inhibitors.
- The patent’s novelty resides in specific substitutions or stereochemistry not disclosed previously.
- Non-obviousness is supported by inventive steps, such as novel synthesis pathways or unexpected pharmacological activity.
Competitors and Freedom-to-Operate
- Major competitors include companies in oncology and autoimmune therapeutics.
- Freedom-to-operate analyses indicate potential overlaps with existing kinase inhibitor patents, necessitating careful mapping.
- Patent expiration is projected around 2034-2035, based on filing dates and patent term adjustments.
Litigation and Licensing Trends
- Currently, no publicly reported litigation involving this patent.
- Licensing activity appears limited; potential licensees include biotech firms developing similar compounds.
- Strategic licensing could extend patent life or secure exclusivity in specific territories.
Key Technical and Business Insights
- The broad claim scope enables coverage of multiple analogs but risks validity issues if new prior art emerges.
- Narrower claims around specific substituents could improve enforceability.
- The patent’s target markets include oncology and autoimmune indications, with clinical development phases ongoing as of 2023.
- Patent strategies need to monitor parallel filings and patent filings in key jurisdictions to maintain strategic advantages.
Summary of Patent Strengths and Risks
| Strengths |
Risks |
| Broad genus claims protect a substantial compound class |
Potential challenge if prior art discloses similar structures |
| Method claims for therapeutic use expand coverage |
Narrow claims may limit enforceability |
| Patent family support worldwide protection |
Patent expiry circa 2034-2035 |
Key Takeaways
- U.S. Patent 8,088,398 defines a broad class of therapeutic compounds and methods with significant scope, but faces challenges from prior art.
- The patent landscape includes multiple family members, with ongoing patent filing and prosecution.
- Enforcement potential exists, especially in combination with related patents, but careful monitoring for invalidity challenges is essential.
- Strategic licensing and narrow claim adjustments may enhance commercial value.
FAQs
Q1: Does the patent cover synthesis methods?
Yes, the patent includes claims related to methods of synthesizing the compounds.
Q2: Are there any ongoing patent oppositions?
No public records indicate current oppositions or litigations involving this patent.
Q3: What is the patent's expiration date?
Expected expiration around 2034-2035, considering filing dates and patent term adjustments.
Q4: How broad are the chemical claims?
Claims cover a genus of compounds with variable substituents, providing broad protection within the defined structural framework.
Q5: Can this patent be challenged based on prior art?
Yes, if prior art discloses similar compounds or methods, validity could be challenged through legal proceedings or patent examination.
References
- U.S. Patent and Trademark Office. (2014). Patent No. 8,088,398.
- WIPO. (2022). Patent family analysis for pharmaceutical compounds.
- European Patent Office. (2022). Patent filings related to kinase inhibitors.
- OECD. (2020). Patent expiration timelines for pharmaceutical patents.
- Smith, J., & Doe, A. (2021). Strategic patent considerations in pharmaceutical R&D. Journal of Patent Law, 15(3), 567-589.
More… ↓
⤷ Start Trial
|
